Remimazolam
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (26)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (79)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (124)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (9)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Early phase / not applicable (1)
What this study did
Competitive landscape
Other GABA-A receptor drugs
Clobazam (Onfi), Diazepam (Diastat), Diazepam (Valium), Diazepam (Valtoco), Ganaxolone and 9 more. Compare all 15 GABA-A receptor drugs
This mechanism is crowded: 14 other tracked programmes target it, 14 of them ahead of this one.
This drug's own stage for Sedation of Mechanically Ventilated ICU Patients: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Remimazolam: this drug | Stage not on record | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Clobazam (Onfi) | Approved(overall) | Small molecule | GABA-A receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Diazepam (Diastat) | Approved(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Diazepam (Valium) | Approved(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Diazepam (Valtoco) | Approved(overall) | Small molecule | GABA-A receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Ganaxolone | Approved(overall) | Small molecule | GABA-A receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Lorazepam | Approved(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Midazolam (Nayzilam) | Approved(overall) | Small molecule | GABA-A receptor, GABA-A receptor (benzodiazepine site) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Phenobarbital Sodium Injection (Sezaby) | Approved(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Stiripentol | Approved(overall) | Small molecule | GABA-A receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Diazepam (Libervant) | Phase 3(overall) | Small molecule | GABA-A receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| KH607 | Phase 3(overall) | Small molecule | GABA-A receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Staccato Alprazolam | Phase 3(overall) | Small molecule | GABA-A receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| GlyphAllo (allopregnanolone Prodrug) (SPT-300) | Phase 2(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HS-10353 | Phase 2(overall) | Small molecule | GABA-A receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Tegileridine | —(overall) | Small molecule | Mu-opioid receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(50 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Remimazolam to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.